Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells $1,005,000.00 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 15,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total value of $1,005,000.00. Following the completion of the sale, the chief executive officer now owns 242,054 shares in the company, valued at $16,217,618. This trade represents a 5.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

David Alan Campbell also recently made the following trade(s):

• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $51.60, for a total value of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00.
• On Friday, September 27th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00.

Janux Therapeutics Stock Down 0.8 %

Shares of NASDAQ:JANX opened at $66.30 on Friday. Janux Therapeutics, Inc. has a twelve month low of $7.79 and a twelve month high of $71.71. The stock’s 50 day moving average is $50.21 and its 200-day moving average is $45.96. The firm has a market capitalization of $3.48 billion, a price-to-earnings ratio of -56.67 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business’s revenue for the quarter was down 82.6% compared to the same quarter last year. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

JANX has been the topic of several recent analyst reports. Scotiabank boosted their target price on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a report on Wednesday. BTIG Research boosted their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday. Stifel Nicolaus raised their target price on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday. UBS Group began coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target on the stock. Finally, Leerink Partners increased their price target on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $79.90.

Hedge Funds Weigh In On Janux Therapeutics

Several large investors have recently added to or reduced their stakes in JANX. Plato Investment Management Ltd increased its holdings in Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after purchasing an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after buying an additional 339 shares in the last quarter. Amalgamated Bank raised its position in Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after buying an additional 368 shares during the last quarter. Summit Securities Group LLC bought a new position in Janux Therapeutics during the 2nd quarter valued at $29,000. Finally, Virtu Financial LLC lifted its stake in Janux Therapeutics by 48.0% during the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after acquiring an additional 2,419 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.